In this study, using several tumor models, we show that an approach combining local RT, srIL-2, IL-12 and anti-CTLA-4, which we call a combined radio- immunotherapy (CRI) regimen, can eradicate tumors with volumes of 2,000 mm3 or larger. Here, CTLA4 is linked to neoplasm.